Co-Diagnostics, Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
CODX$0.32+24.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statement of Changes in Stockholders’ Equity
| Convertible Preferred Stock · Common Stock · Treasury · Additional Paid-in · Accumulated Other Comprehensive · Accumulated Earnings · TotalStockholders’ | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount · Stock · Capital · Income · (Deficit) · Equity | |||||||||||
| Balance as of December 31, 2023 | - | $ | - | 1,203,611 | $36,108 | $(15,575,795) | $96,808,436 | $146,700 | $4,161,405 | $85,576,854 | |
| Issuance of common stock related to at-the-market offering, net of offering costs | - | - | 10,491 | 315 | - | 230,349 | - | - | 230,664 | ||
| Stock-based compensation expense | - | - | 49,306 | 1,479 | - | 5,433,425 | - | - | 5,434,904 | ||
| Other comprehensive loss, net of tax | - | - | - | - | - | - | 271,743 | - | 271,743 | ||
| Net loss | - | - | - | - | - | - | - | (37,639,008) | (37,639,008) | ||
| Balance as of December 31, 2024 | - | $ | - | 1,263,408 | $37,902 | $(15,575,795) | $102,472,210 | $418,443 | $(33,477,603) | $53,875,157 | |
| Common stock issued for option exercises | - | - | 758 | 23 | - | 12,477 | - | - | 12,500 | ||
| Issuance of common stock related to at-the-market offering, net of offering costs | - | - | 172,852 | 5,185 | - | 1,678,878 | - | - | 1,684,063 | ||
| Stock-based compensation expense | - | - | 58,092 | 1,743 | - | 2,246,310 | - | - | 2,248,053 | ||
| Issuance of common stock related to financial advisory services | - | - | 16,667 | 500 | - | 134,500 | - | - | 135,000 | ||
| Issuance of common stock related to registered direct offering, net of offering costs | - | - | 744,877 | 22,347 | - | 9,965,923 | - | - | 9,988,270 | ||
| Other comprehensive loss, net of tax | - | - | - | - | - | - | (418,443) | - | (418,443) | ||
| Net loss | - | - | - | - | - | - | - | (46,895,936) | (46,895,936) | ||
| Balance as of December 31, 2025 | - | $ | - | 2,256,654 | $67,700 | $(15,575,795) | $116,510,298 | $ | - | $(80,373,539) | $20,628,664 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.